Sana Biotechnology (NASDAQ:SANA) Receives Market Outperform Rating from JMP Securities

Sana Biotechnology (NASDAQ:SANA)‘s stock had its “market outperform” rating reissued by investment analysts at JMP Securities in a report issued on Tuesday,Benzinga reports. They currently have a $5.00 target price on the stock. JMP Securities’ target price would indicate a potential upside of 90.62% from the company’s current price.

Several other equities analysts have also weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and set a $11.00 price objective on shares of Sana Biotechnology in a research report on Thursday, April 24th. Jefferies Financial Group assumed coverage on shares of Sana Biotechnology in a research note on Friday, March 14th. They issued a “buy” rating and a $7.00 price objective on the stock. Finally, Citizens Jmp upgraded Sana Biotechnology from a “market perform” rating to an “outperform” rating and set a $5.00 price objective for the company in a research report on Tuesday, March 18th. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $9.83.

Sana Biotechnology Stock Up 0.9%

Shares of Sana Biotechnology stock opened at $2.62 on Tuesday. Sana Biotechnology has a 12 month low of $1.26 and a 12 month high of $7.40. The stock has a market cap of $591.43 million, a PE ratio of -3.04 and a beta of 1.78. The business has a fifty day simple moving average of $2.09 and a 200-day simple moving average of $2.34.

Sana Biotechnology (NASDAQ:SANA) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.02. Analysts expect that Sana Biotechnology will post -1.16 EPS for the current fiscal year.

Institutional Trading of Sana Biotechnology

Hedge funds and other institutional investors have recently made changes to their positions in the business. Rhumbline Advisers raised its position in shares of Sana Biotechnology by 5.4% during the first quarter. Rhumbline Advisers now owns 182,134 shares of the company’s stock worth $306,000 after acquiring an additional 9,359 shares during the last quarter. SCS Capital Management LLC bought a new position in Sana Biotechnology during the 1st quarter worth approximately $137,000. Woodline Partners LP grew its holdings in shares of Sana Biotechnology by 13.1% in the 1st quarter. Woodline Partners LP now owns 780,656 shares of the company’s stock valued at $1,312,000 after buying an additional 90,515 shares during the period. Clearline Capital LP bought a new stake in shares of Sana Biotechnology in the first quarter worth about $690,000. Finally, AQR Capital Management LLC increased its stake in Sana Biotechnology by 49.8% during the 1st quarter. AQR Capital Management LLC now owns 573,146 shares of the company’s stock worth $963,000 after purchasing an additional 190,483 shares in the last quarter. 88.23% of the stock is currently owned by institutional investors and hedge funds.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.